Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.
about
Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine designAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesMutations that destabilize the gp41 core are determinants for stabilizing the simian immunodeficiency virus-CPmac envelope glycoprotein complexStructure of the HIV-1 gp41 Membrane-Proximal Ectodomain Region in a Putative Prefusion Conformation † , ‡Extensive Mutagenesis of the HSV-1 gB Ectodomain Reveals Remarkable Stability of Its Postfusion FormA next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodiesHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesDNA vaccines against human immunodeficiency virus type 1.Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin.Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunityStoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.Functional chimeras of human immunodeficiency virus type 1 Gp120 and influenza A virus (H3) hemagglutininCharacterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins.Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1Single-particle cryoelectron microscopy analysis reveals the HIV-1 spike as a tripod structure.Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins.Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins.Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particlesChanges in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable regionDense display of HIV-1 envelope spikes on the lambda phage scaffold does not result in the generation of improved antibody responses to HIV-1 Env.Structure-based vaccine design in HIV: blind men and the elephant?Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin.Receptor binding domain based HIV vaccines.Probing the HIV gp120 envelope glycoprotein conformation by NMR.A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.Fusion-induced apoptosis contributes to thymocyte depletion by a pathogenic human immunodeficiency virus type 1 envelope in the human thymus.Immunization of rabbits with highly purified, soluble, trimeric human immunodeficiency virus type 1 envelope glycoprotein induces a vigorous B cell response and broadly cross-reactive neutralization.Effects of the I559P gp41 change on the conformation and function of the human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimer.Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization.Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus MacaquesCharacterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicityHIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost.A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.
P2860
Q24679395-26EE73E4-394E-4B6B-87DE-518CD9F3B2F2Q27489000-BA070F1F-097C-444A-B873-943663FACD01Q27637675-F93270AB-4E09-465F-8DEF-B696EE70ECD0Q27653846-852C853B-7374-4BC3-B297-1786027A895DQ27676847-5E8DD199-281E-4672-94CA-C90020F97C3EQ28299280-89FD02BB-0CFF-44EF-BF48-2F601EDA8D06Q29619015-6421BAC6-4579-4DCA-93D7-ED4C2344478AQ30342130-D892D6F6-DF80-46FC-A309-27256B37CF6DQ30353580-5BA64300-9E0A-4E04-BDDC-8D3FE93EDAC4Q30393406-CD8B68ED-6881-4D9B-AD22-8C3C32A0CBFBQ30399285-CD3904A6-78B8-4033-9B05-971D332E36D5Q30447936-ACA01C06-DD59-4454-9FB6-B75CE8473A7DQ30490942-08939D24-91B0-4A5A-B873-5931D849B3B0Q33571825-C71878D1-5A5D-4B1D-8830-0F91EE7F3A06Q33780529-C343B2FB-2F13-440D-8A37-F6A5BE5C30FBQ33806056-BB20D17C-D183-4327-973B-D82AE9979938Q33836042-26276BBA-7E4B-4F56-AA0C-08C2AE8E7115Q33883887-61EA654C-3897-49BC-A2DA-56D6CB2C6979Q34279140-1A24C83E-38F2-4834-9850-817B605CDE1EQ34332284-B7FAB41E-4B01-47D5-AB77-6DF937FBF9CCQ34332728-50BEA359-1635-4EE0-B2B5-176CE661D0E2Q34334135-8EF890F1-0BFD-4FA6-B30E-487B223EEADEQ34361680-FB384837-D83A-474F-8C52-1D17622B6382Q34391256-545C52F0-C809-4482-8F09-905AA0EBF79CQ34465510-17F65E1E-E7E5-439A-916A-CB8634E30E6CQ34471760-0196379E-6EC6-45C3-AD8A-22341AB0F664Q34706815-20780920-814A-4665-83AE-F89FF2CD4CBDQ34987048-520EC906-E854-4B6C-8595-ABD6DC3AD4C7Q34999293-06048E9D-E016-4AB8-91BF-7263835F7E3CQ35033862-7D5F3DCC-02B7-4E83-AA59-80E67F82C11BQ35085066-CDE8164A-DFFD-49A0-A2F8-29BD0A970221Q35110976-2CAD7D2D-64C9-4CA1-8BA6-EB0C60ED4426Q35139607-0F94B756-332E-4330-8DFE-A568FE396D62Q35171701-BCB79240-C4E1-4769-9A2B-CA803B18AFC1Q35596474-E54E3E59-0B19-49D2-9EE6-20CA041D22EFQ35691113-04414753-B0EE-47ED-8C7D-E847755B649DQ35826692-C999359D-FD38-42A2-B068-4479F08A9BF6Q35857631-EE8D0C78-8109-41F8-9D56-3961CB87B7C1Q35883997-CA9286D0-D51F-4012-8B75-E77878F82E3CQ36149102-389C7A33-0566-4FD2-8ED5-5581625F54C2
P2860
Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Modifications that stabilize h ...... coprotein trimers in solution.
@ast
Modifications that stabilize h ...... coprotein trimers in solution.
@en
type
label
Modifications that stabilize h ...... coprotein trimers in solution.
@ast
Modifications that stabilize h ...... coprotein trimers in solution.
@en
prefLabel
Modifications that stabilize h ...... coprotein trimers in solution.
@ast
Modifications that stabilize h ...... coprotein trimers in solution.
@en
P2093
P2860
P1433
P1476
Modifications that stabilize h ...... coprotein trimers in solution.
@en
P2093
P2860
P304
P356
10.1128/JVI.74.10.4746-4754.2000
P577
2000-05-01T00:00:00Z